knowledge -WSS

knowledge

author：Wikipedia 2025-09-30 00:37:29 - browse：883

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Study on Amgen’s bispecific immunotherapy produces positive data

WSS

Study: Black kids more likely to die after surgery than white kids

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Why a market frenzy over new weight loss drugs defies logic

Hundreds died while taking an arthritis drug, but nobody alerted patients

Results on Novartis prostate cancer therapy could expand its use

ADCs take center stage as promising cancer treatments

Wikipedia

knowledge

explore

Psychedelics group wrestles with new pharma identity

Florida Supreme Court upholds state's abortion ban

United colonoscopy coverage change 'may cost lives,' doctors say

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Hepatitis C has a cure — but many Americans still lack access to it

Hundreds died while taking an arthritis drug, but nobody alerted patients

Bright Health sells Medicare Advantage business to Molina

STAT Summit: Ending the crisis of Black deaths in the U.S.

Duchenne breakthrough therapy leaves behind pioneering families

STAT Readout: Friday, Oct. 20 biotech updates

leisure time

Mass General Brigham physicians react to latest merger step

Roche drug slashes death risk in early

People with mental disorders often marry others with same

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Study: Black kids more likely to die after surgery than white kids

Roche drug slashes death risk in early

hotspot

focus

hotspot

explore